Abstract
Multidrug resistance (MDR) to antitumor agents represents a significant challenge to effective chemotherapy. The use of MDR modulators is a promising approach to overcome the undesired MDR phenotype. The more effective MDR modulators are urgently needed for clinical use. This review focuses on literatures published in 1998-2001.
Keywords: Multidrug Resistance, chemotherapy, MDR phenotype, antitumor agents
Current Drug Targets
Title: New Multidrug Resistance Reversal Agents
Volume: 4 Issue: 1
Author(s): Masami Kawase and Noboru Motohashi
Affiliation:
Keywords: Multidrug Resistance, chemotherapy, MDR phenotype, antitumor agents
Abstract: Multidrug resistance (MDR) to antitumor agents represents a significant challenge to effective chemotherapy. The use of MDR modulators is a promising approach to overcome the undesired MDR phenotype. The more effective MDR modulators are urgently needed for clinical use. This review focuses on literatures published in 1998-2001.
Export Options
About this article
Cite this article as:
Kawase Masami and Motohashi Noboru, New Multidrug Resistance Reversal Agents, Current Drug Targets 2003; 4 (1) . https://dx.doi.org/10.2174/1389450033347064
DOI https://dx.doi.org/10.2174/1389450033347064 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Autoimmune Diseases in Gastroenterology
Current Pharmaceutical Design Arterial Ischemic Stroke in Neonates and Children: Review and Current Issues
Current Pediatric Reviews Synthesis, in Vitro and in Vivo Anticancer Activity of Hybrids of 3- Hydroxy-indolin-2-one and 2,3-Dihydroquinolin-4(1H)-one
Letters in Drug Design & Discovery Anti-breast Cancer Potential of Natural and Synthetic Coumarin Derivatives
Current Topics in Medicinal Chemistry Nutrition in Adult Patients with Inflammatory Bowel Disease
Current Drug Targets An Emerging Molecular Target in Melanoma: Cellular Carbonyl Stress and the Inhibition of Mitochondrial Survival Pathways by Carbonyl Scavenger Agents
Current Cancer Therapy Reviews Oxaliplatin-mediated Inhibition of Survivin Increases Sensitivity of Head and Neck Squamous Cell Carcinoma Cell Lines to Paclitaxel
Current Cancer Drug Targets A Network-Based Cancer Drug Discovery: From Integrated Multi-Omics Approaches to Precision Medicine
Current Pharmaceutical Design Regulation of miRNA Processing and miRNA Mediated Gene Repression in Cancer
MicroRNA The Chemopreventive and Chemotherapeutic Potentials of Tea Polyphenols
Current Pharmaceutical Biotechnology Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Nitric Oxide and Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) Synthetic Strategies Towards O6-Substituted Guanine Derivatives and their Application in Medicine
Current Organic Synthesis <i>In Vitro</i> Anticancer Activity of Virgin Coconut Oil and its Fractions in Liver and Oral Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Effects of Estrogens on Atherogenesis
Current Vascular Pharmacology Inhibitors of the Proteolytic Activity of Urokinase Type Plasminogen Activator
Current Pharmaceutical Design MicroRNA Regulation of Programmed Cell Death Pathways in Cancer
Current Chemical Biology Choline Kinase Alpha Depletion Selectively Kills Tumoral Cells
Current Cancer Drug Targets Biodistribution and Tumor Targeting of Indium and Iodine-labeled Shiga Toxin B-Subunit
Current Radiopharmaceuticals Antisense Oligonucleotides in the Treatment of Cerebral Gliomas. Review of Concerning Patents
Recent Patents on CNS Drug Discovery (Discontinued)